Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Keytruda® (pembrolizumab) – New indication
April 22, 2019 - Merck announced the FDA approval of Keytruda (pembrolizumab), in combination with Inlyta® (axitinib), for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
